Previous 10 | Next 10 |
Otonomy Inc. (NASDAQ:OTIC) traded today at a new 52-week low of $1.66. Approximately 335,000 shares have changed hands today, as compared to an average 30-day volume of 345,000 shares. Otonomy Inc. share prices have moved between a 52-week high of $6.98 and the current low of $1.66 and a...
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2021 and provide a corporate update at...
Otonomy Inc. (NASDAQ:OTIC) traded at a new 52-week low today of $1.80. So far today approximately 335,000 shares have been exchanged, as compared to an average 30-day volume of 342,000 shares. Over the past year, Otonomy Inc. has traded in a range of $1.80 to $6.98 and is now at $1.83. ...
Shares of Otonomy Inc. (NASDAQ:OTIC) traded at a new 52-week low today of $1.88. Approximately 335,000 shares have changed hands today, as compared to an average 30-day volume of 321,000 shares. Otonomy Inc. share prices have moved between a 52-week high of $6.98 and the current low of $...
Otonomy Inc. (NASDAQ:OTIC) traded today at a new 52-week low of $1.97. So far today approximately 335,000 shares have been exchanged, as compared to an average 30-day volume of 301,000 shares. There is potential upside of 26.5% for shares of Otonomy Inc. based on a current price of $2.00...
Shares of Otonomy Inc. (NASDAQ:OTIC) traded today at $2.00, breaking its 52-week low. So far today approximately 335,000 shares have been exchanged, as compared to an average 30-day volume of 296,000 shares. Potential upside of 24.0% exists for Otonomy Inc., based on a current level of $...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Otonomy (OTIC) announces the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-in-noise hearing difficulty.Shares up more than 10% premarket.OTO-413 is a proprietary, sustained-exposure formulation of brain-derived neurotrophic...
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohort Expansion study will support endpoint selection and powering for Phase 2 Top-line results expected in mid-20...
Otonomy (OTIC) announces preclinical proof-of-concept results for OTO-825 at the ASGCT Annual Meeting. OTO-825 is an AAV-mediated gene therapy developed in collaboration with Applied Genetic Technologies Corporation (AGTC).The results demonstrate that a single administration of OTO-825 rescue...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...